{{Rsnum
|rsid=10932125
|Gene=NRP2
|Chromosome=2
|position=205787576
|Orientation=plus
|GMAF=0.3907
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=NRP2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 33.3 | 43.3 | 23.3
| HCB | 38.6 | 47.7 | 13.6
| JPT | 36.4 | 52.3 | 11.4
| YRI | 48.2 | 46.4 | 5.4
| ASW | 0.0 | 0.0 | 0.0
| CHB | 38.6 | 47.7 | 13.6
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10932125
|Name_s=
|Gene_s=NRP2
|Feature=
|Evidence=PubMed ID:18451141
|Annotation=This SNP at chromosome 2 is significantly associated with CYP1B1 expression (located on chromosome 2), and daunorubicin IC50 in CEU population using International HapMap cell lines.
|Drugs=daunorubicin
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA162263546
}}{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10932125
|overall_frequency_n=39
|overall_frequency_d=124
|overall_frequency=0.314516
|n_genomes=33
|n_genomes_annotated=0
|n_haplomes=38
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}